Secondary Hypogonadism Clinical Trial
Official title:
An Open Label, 6 Month Phase III Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
To determine the safety profile of Androxal in men with secondary hypogonadism.
This study is an open-label, multi-center Phase 3 extension study to evaluate the safety on continued treatment with Androxal in subjects who completed either ZA-301 or ZA-302. The study requires 6 study visits (1 for an eye exam) and is approximately 7 months in duration. Subjects will be treated for 26 weeks, starting at a daily dose of 12.5 mg. At Visit 2 (Week 6) subjects who do not achieve morning T values ≥450 ng/dL will be up-titrated to 25 mg. Safety will be assessed by physical and visual acuity exams, slit lamp and fundoscopy, refraction eye exams, clinical laboratory tests and adverse event reporting. ;
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01454011 -
The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups
|
Phase 4 | |
| Completed |
NCT01191320 -
Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus
|
Phase 2 | |
| Completed |
NCT01739595 -
Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism
|
Phase 3 | |
| Active, not recruiting |
NCT02443090 -
Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men
|
Phase 2 | |
| Completed |
NCT01534208 -
Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
|
Phase 3 | |
| Completed |
NCT00962637 -
Study to Evaluate the Safety and Efficacy of Androxalâ„¢ Treatment in Men With Secondary Hypogonadism
|
Phase 3 | |
| Completed |
NCT00467870 -
Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men
|
Phase 3 | |
| Completed |
NCT01067365 -
Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism
|
Phase 3 | |
| Completed |
NCT01386606 -
The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)
|
Phase 2 | |
| Completed |
NCT00706719 -
To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone
|
Phase 2 | |
| Completed |
NCT00911586 -
Pharmacokinetic Study to Determine Time to Steady-state
|
Phase 2 | |
| Completed |
NCT01993212 -
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
|
Phase 3 | |
| Completed |
NCT01993225 -
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
|
Phase 3 | |
| Completed |
NCT01270841 -
Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism
|
Phase 2 | |
| Completed |
NCT02274181 -
An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration
|
Phase 1 | |
| Completed |
NCT01923870 -
Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function
|
Phase 1 | |
| Completed |
NCT01923857 -
Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function
|
Phase 1 | |
| Completed |
NCT01532414 -
Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism
|
Phase 3 |